C12ORF65 Gene SPG55 NGS Genetic DNA Test
Comprehensive Genetic Testing for Hereditary Spastic Paraplegia
The C12ORF65 Gene SPG55 NGS Genetic DNA Test represents a breakthrough in neurological genetic diagnostics, offering precise identification of mutations responsible for SPG55, a specific subtype of hereditary spastic paraplegia. This advanced testing methodology utilizes next-generation sequencing technology to provide unparalleled accuracy in detecting genetic variations that contribute to progressive neurological deterioration.
What Does This Test Measure?
This specialized genetic test specifically analyzes the C12ORF65 gene for pathogenic variants associated with SPG55 hereditary spastic paraplegia. The test examines:
- Point mutations and single nucleotide variants in the C12ORF65 gene
- Insertions and deletions that may disrupt gene function
- Splice site mutations affecting protein production
- Complex genetic rearrangements impacting neurological function
- Inheritance patterns and familial risk assessment
Who Should Consider This Test?
This genetic test is particularly recommended for individuals experiencing:
- Progressive difficulty walking or gait abnormalities
- Muscle stiffness and spasticity in lower limbs
- Family history of hereditary spastic paraplegia
- Unexplained neurological symptoms beginning in childhood or early adulthood
- Progressive weakness in leg muscles without clear diagnosis
- Balance and coordination issues with gradual onset
- Family members of diagnosed SPG55 patients seeking carrier status
Clinical Benefits of Genetic Testing
Undergoing the C12ORF65 Gene SPG55 NGS Genetic DNA Test provides numerous clinical advantages:
- Accurate Diagnosis: Precise identification of SPG55 mutations eliminates diagnostic uncertainty
- Early Intervention: Enables proactive management strategies before significant disability develops
- Personalized Treatment: Guides targeted therapeutic approaches based on specific genetic findings
- Family Planning: Provides crucial information for reproductive decision-making
- Prognostic Insight: Helps predict disease progression and potential complications
- Clinical Trial Eligibility: Opens opportunities for participation in specialized treatment studies
Understanding Your Test Results
Our comprehensive genetic counseling services help you interpret your results effectively:
- Positive Result: Indicates presence of pathogenic C12ORF65 mutation, confirming SPG55 diagnosis
- Negative Result: Suggests absence of known SPG55 mutations, though other genetic causes may exist
- Variant of Uncertain Significance: Identifies genetic changes requiring further clinical correlation
- Carrier Status: Determines risk of passing the condition to future generations
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $700 |
Nationwide Testing Accessibility
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified genetic counselors and neurological specialists ensures comprehensive care coordination regardless of your location.
Take Control of Your Neurological Health
Don’t let uncertainty about hereditary spastic paraplegia impact your quality of life. Early genetic testing provides the clarity needed for effective management and informed healthcare decisions. Our team of genetic specialists and neurologists is ready to guide you through the testing process and help you understand your results.
Call +1(267) 388-9828 today to schedule your C12ORF65 Gene SPG55 NGS Genetic DNA Test and take the first step toward definitive diagnosis and personalized care.
